Acuitas Therapeutics Acquires Majority Stake in RNA Technologies & Therapeutics
January 9, 2026
Acuitas Therapeutics has acquired a majority stake in RNA Technologies & Therapeutics (RNA T&T), deepening a long-standing collaboration to integrate RNA payload design and LNP delivery capabilities. The investment will support RNA T&T's growth—expanding its algorithmic RNA-sequence optimization platform and small-batch GMP production—while both companies continue to operate independently and offer streamlined capabilities to partners.
- Buyers
- Acuitas Therapeutics
- Targets
- RNA Technologies & Therapeutics (RNA T&T)
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Valerio Therapeutics Acquires Etherna Immunotherapies
August 17, 2026
Biotechnology
Valerio Therapeutics acquired 100% of Etherna Immunotherapies at an enterprise value of €30 million, funded through cash consideration and contributions of Etherna shares. The acquisition combines Valerio’s cell-targeting technology with Etherna’s RNA chemistry, lipid nanoparticle delivery and GMP manufacturing capabilities to build an integrated targeted RNA therapeutics platform.
-
Eclipsebio Acquires Terrain Bio
January 29, 2026
Biotechnology
Eclipse Bioinnovations (Eclipsebio) has acquired Terrain Bio to integrate Terrain's AI/ML RNA design models and R&D-scale mRNA manufacturing analytics into Eclipsebio's sequencing-based validation platforms. The deal creates an end-to-end Design, Make, Test platform intended to accelerate RNA therapeutic development by connecting computational design directly to experimental feedback.
-
Novartis Acquires DTx Pharma
July 17, 2023
Biotechnology
Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.
-
TA Associates Makes Strategic Growth Investment in Diatech Pharmacogenetics
April 26, 2023
Biotechnology
TA Associates has signed a definitive agreement to make a strategic growth investment in Diatech Pharmacogenetics, a Jesi, Italy–based developer and manufacturer of molecular diagnostics for precision oncology. Minority investor Alto Partners will fully exit while Diatech's founder and management retain majority ownership; the capital will support product development and international expansion.
-
AbCellera Acquires TetraGenetics
September 13, 2021
Biotechnology
AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.
-
BioNTech Acquires Neon Therapeutics
January 16, 2020
Biotechnology
BioNTech SE will acquire Neon Therapeutics, Inc. in an all-stock transaction valued at approximately $67.0 million. Neon, a Cambridge-based developer of neoantigen-targeted T cell therapies, will become a wholly owned subsidiary of BioNTech to expand BioNTech’s T cell therapy capabilities and U.S. presence.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.